HIV-1 associated Topoisomerase IIβ kinase: A potential pharmacological target for viral replication

Current Pharmaceutical Design

Volumn 19, Issue 26, 2013, Pages 4776-4786

  Ponraj, Kannapiran ^a   Prabhakar, Maddela ^a   Rathore, R S ^a   Bommakanti, Akhila ^a   Kondapi, Anand K ^a  

^a UNIVERSITY OF HYDERABAD   (India)

Author keywords

HIV 1; HIV 1 associated Topoisomerase II kinase; HIV 1 Topoisomerase II ; QSAR; Synthesis of anti HIV and anti kinase inhibitors; Topoisomerase II

Indexed keywords

2 AMINO 3 HYDROXYPYRIDINE; 2 METHOXYPYRIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 5 IODOTUBERCIDIN; ANTIRETROVIRUS AGENT; CYCLIC AMP DEPENDENT PROTEIN KINASE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DOUBLE STRANDED DNA; HYPERICIN; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIDINE DERIVATIVE; RETINOIC ACID; SINGLE STRANDED DNA; STAUROSPORINE; TOPOISOMERASE II BETA KINASE; UNCLASSIFIED DRUG; VIRUS PROTEIN; WORTMANNIN;

AMINO ACID SEQUENCE; ANTIVIRAL ACTIVITY; ARTICLE; BOOTSTRAPPING; CELL CYCLE; CELL DIVISION; CELL MATURATION; CELL PROLIFERATION; CHEMICAL ANALYSIS; COMPARATIVE MOLECULAR FIELD ANALYSIS; CYTOTOXICITY; DRUG POTENCY; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SPECIFICITY; GENE EXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IN VITRO STUDY; LIFE CYCLE; NONHUMAN; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PURIFICATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SOLVATION; STRUCTURE ACTIVITY RELATION; SUMOYLATION; VIRUS REPLICATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CATALYTIC DOMAIN; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; HIV-1; PHOSPHORYLATION; PYRIDINES; VIRUS REPLICATION;

EID: 84881366410     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319260008     Document Type: Article

References (59)

1. Kondapi AK, Padmaja G, Satyanarayana N, Mukhopadyaya R, Reitz MS. A biochemical analysis of topoisomerase II alpha and beta kinase activity found in HIV-1 infected cells and virus. Arch Biochem Biophys 2005; 441: 41-55.
2. Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. Nat Rev Mol Cell Biol 2002; 3: 430-40.
3. Cerritelli SM, Chon H, Crouch RJ. A New Twist for Topisomerase 1: Topoisomerase creates 2-5 base pair deletions by attacking ribonucleotides in DNA. Science 2011; 332: 1510-1.
4. Kim N, Huang SN, Williams JS, et al. Mutagenic Processing of Ribonucleotides in DNA by Yeast Topoisomerase I. Science 2011; 332: 1561.
5. Pommier YE, Leo E, Zhang HL, Marchand C. DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs. Chem Biol 2010; 17: 421-33.
6. Collins TR, Hammes GG, Hsieh TS. Analysis of the eukaryotic topoisomerase II DNA gate: a single-molecule FRET and structural perspective. Nucleic Acids Res 2009; 37: 712-20.
7. Romanienko PJ, Camerini-Otero RD. Cloning, Characterization, and Localization of Mouse and Human SPO11. Genomics 1999; 61: 156-69.
8. Nolan JM, Lee MP, Wyckoff E, Hsieh TS. Isolation and characterization of the gene encoding Drosophila DNA topoisomerase II. Proc Natl Acad Sci USA 1986; 83: 3664-8.
9. Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989; 86: 9431-5.
10. Woessner RD, Chung TD, Hofmann GA, et al. Differences between Normal and ras-transformed NIH-3T3 Cells in Expression of the 170kD and 180kD Forms of Topoisomerase II. Cancer research 1990; 50: 2901-8.
11. Tan KB, Dorman TE, Falls KM, et al. Topoisomerase II and Topoisomerase IIα Genes: Characterization and Mapping to Human Chromosomes 17 and 3, Respectively. Cancer Res 1992; 52: 231-4.
12. Akimitsu N, Adachi N, Hirai H, et al. Enforced cytokinesis without complete nuclear division in embryonic cells depleting the activity of DNA topoisomerase II. Genes Cells 2003; 8: 393-402.
13. Lyu YL, Wang JC. Aberrant lamination in the cerebral cortex of mouse embryos lacking DNA topoisomerase IIbeta. Proc Natl Acad Sci USA 2003; 100: 7123-8.
14. Drake FH, Hofmann GA, Bartus HF, Mattern MR, Crooke ST, Mirabelli CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989; 28: 8154-60.
15. Capranico G, Tinelli S, Austin CA, Fisher ML, Zunino F. Different patterns of gene expression of topoisomerase II isoforms in differentiated tissues during murine development. Biochim Biophys Acta 1992; 1132: 43-8.
16. Woessner RD, Mattern MR, Mirabelli CK, Johnson RK, Drake FH. Proliferation-and cell cycle-dependent differences in expression of the 170 kilodalton and 180 kilodalton forms of topoisomerase II in NIH-3T3 cells. Cell Growth Differ 1991; 2: 209-14.
17. Sakaguchi A, Kikuchi A. Functional compatibility between isoform alpha and beta of type II DNA topoisomerase. J Cell Sci 2004; 117: 1047-54.
18. Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. Nat Rev Cancer 2009; 9: 327-37.
19. Darby MK, Schmitt B, Jongstra-Bilen J, Vosberg HP. Inhibition of calf thymus type II DNA topoisomerase by poly (ADPribosylation). The EMBO J 1985; 4: 2129-34.
20. Ackerman P, Glover CV, Osheroff N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci USA 1985; 82: 3164-8.
21. Sahyoun N, Wolf M, Besterman J, et al. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 1986; 83: 1603-7.
22. Ackerman P, Glover CVC, Osheroff N. Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. Proc Natl Acad Sci USA 1985; 82: 3164-8.
23. Sahyoun N, Wolf M, Besterman J, et al. Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells. Proc Natl Acad Sci USA 1986; 83:1603-7.
24. Gasser SM, Walter R, Dang Q, Cardenas ME. Topoisomerase II: its functions and phosphorylation. Antonie Van Leeuwenhoek 1992; 62: 15-24.
25. McNamara S, Wangc H, Hanna N, Miller WH. Topoisomerase IIα Negatively Modulates Retinoic Acid Receptor Function: a Novel Mechanism of Retinoic Acid Resistance. Mol Cell Biol 2008; 28: 2066-77.
26. Wang P, Rennekamp AJ, Yuan Y, Lieberman PM. Topoisomerase I and RecQL1 function in Epstein-Barr virus lytic reactivation. J Virol 2009; 83: 8090-8.
27. Lee JC, Adams JL. Inhibitors of serine/threonine kinases. Curr Opin Biotechnol 1995; 6: 657-61.
28. Advani SJ, Weichselbaum RR, Roizman B. Herpes simplex virus 1 activates cdc2 to recruit topoisomerase II alpha for post-DNA synthesis expression of late genes. Proc Natl Acad Sci USA 2003; 100: 4825-30.
29. Fortune JM, Lavrukhin OV, Gurnon JR, Van Etten JL, Lloyd RS, Osheroff N. Topoisomerase II from Chlorella virus PBCV-1 has an exceptionally high DNA cleavage activity. J Biol Chem 2001; 276: 24401-8.
30. Bouillé P, Subra F, Mouscadet JF, Auclair C. Antisense-mediated repression of DNA topoisomerase II expression leads to an impairment of HIV-1 replicative cycle. J Mol Biol 1999; 285: 945-54.
31. Kondapi AK, Satyanarayana N, Saikrishna AD. A study of the Topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes. Arc biochem biophys 2006; 450: 123-32.
32. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298: 1912-34.
33. Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988; 241: 42-52.
34. al-Obeidi FA, Wu JJ, Lam KS. Biopolymers 1998; 47: 197-223.
35. Zuccotto F, Ardini E, Casale E, Angiolini M. Through the "gatekeeper door": exploiting the active kinase conformation. J Med Chem 2010; 53: 2681-94.
36. Scior T, Medina-Franco JL, Do QT, et al. How to recognize and workaround pitfalls in QSAR studies: a critical review. Curr Med Chem 2009; 16: 4297-313.
37. Silipo C, Hansch C. Correlation analysis. Its application to the structure-activity relationship of triazines inhibiting dihydrofolate reductase. J Am Chem Soc 1975; 97: 6849-61.
38. Barnitz RA, Wan F, Tripuraneni V, Bolton DL, Lenardo MJ. Protein kinase A phosphorylation activates Vpr-induced cell cycle arrest during human immunodeficiency virus type 1 infection. J Virol 2010; 84: 6410-24.
39. Park GH, Lee YT, Bae YS. Mediator, not holoenzyme, is directly recruited to the heat shock promoter by HSF upon heat shock. Mol Cell 2001; 11: 82-8.
40. Saijo M, Enomoto T, Hanaoka F, Ui M. Purification and characterization of type II DNA topoisomerase from mouse FM3A cells: phosphorylation of topoisomerase II and modification of its activity. Biochemistry 1990; 29: 583-90.
41. Levitzki A. Protein kinase inhibitors as a therapeutic modality. Accounts Chem Res 2003; 36: 462-9.
42. Dang Q, Alghisi GC, Gasser SM. Phosphorylation of the Cterminal domain of yeast topoisomerase II by casein kinase II affects DNA-protein interaction. J Mol Biol 1994; 243: 10-24.
43. Alghisi GC, Roberts E, Cardenas ME, Gasser SM. The regulation of DNA topoisomerase II by casein kinase II. Cell Mol Biol Res 1994; 40: 563-71.
44. Cardenas ME, Gasser SM. Regulation of topoisomerase II by phosphorylation: a role for casein kinase II. J Cell Sci 1993; 104 (Pt 2): 219-25.
45. Daum JR, Gorbsky GJ. Casein kinase II catalyzes a mitotic phosphorylation on threonine 1342 of human DNA topoisomerase II alpha, which is recognized by the 3F3/2 phosphoepitope antibody. J Biol Chem 1998; 273: 30622-9.
46. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotech 2008; 26: 127-32.
47. Padmaja G. Identification and characterization of Topoisomerase II alpha and beta kinase activity in HIV-1 infected cells and virus particles. 2006; Ph. D thesis, University of Hyderabad, Hyderabad, India.
48. Aronov A, Mcclain B, Moody C, Murcko M. Kinase-likeness and kinase-privileged fragments: toward virtual polypharmacology. J Med Chem 2008; 51: 1214-22.
49. Hanks SK, Hunter T. Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. The FASEB journal 1995; 9: 576-96.
50. Biondi RM, Nebreda AR. Signaling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J 2003; 372: 1-13.
51. Vulpetti A, Bosotti R. Sequence and structural analysis of kinase ATP pocket residues. Farmaco 2004; 59: 759-65.
52. Stahura FL, Xue L, Godden JW, Bajorath J. Methods for compound selection focused on hits and application in drug discovery. J Mol Graph Model 1999; 17: 1-9, 51-2.
53. Babu PA, Narasu LM, Srinivas K. Pyridines, pyridazines and guanines as CDK2 inhibitors: a review. Arkivoc 2007; (ii): 247-65.
54. Bilodeau MT, Rodman LD, McGaughey GB, et al. The discovery of N-(1,3-thiazol-2-yl)pyridin-2-amines as potent inhibitors of KDR kinase Bioorg Med Chem Lett 2004; 14: 2941-5.
55. Metobo SE, Jin H, Tsiang M, Kim CU. Design, synthesis, and biological evaluation of novel tricyclic HIV-1 integrase inhibitors by modification of its pyridine ring. Bioorg Med Chem Lett 2006; 16: 3985-8.
56. Deeb O, Clare BW. QSAR of heterocyclic antifungal agents by flip regression. J Comput Aided Mol Des 2008; 22: 885-95.
57. Kuo GH, Prouty C, Wang A, et al. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. J Med Chem 2005; 48: 4892-909.
58. Balzarini J, Stevens M, De Clercq E, Schols D, Pannecouque C. Pyridine N-oxide derivatives: unusual anti-HIV compounds with multiple mechanisms of antiviral action. J Antimicrob Chemother 2005; 55: 135-8.
59. Cai ZW, Wei D, Schroeder GM, et al. Discovery of orally active pyrrolopyridine-and aminopyridine-based Met kinase inhibitors. Bioorg Med Chem Lett 2008; 18: 3224-9.